Production assistance for cellular therapies (PACT)- cell processing facilities cell manufacturing and process development services for PCT0025-01: fviii TCR-engineered treg cell product
Ended Awarded Last action
- Contract number
- 75N92019F00074
- Awardee
-
H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. UEI DVHKP4N619V9
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $761,385
Award facts
- Opportunity
-
- 75N92019R015 Solicitation number
- Contract value 100% obligated
- $761,385.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Tampa, FL 33612, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Funding Only Action | -$82,309 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $843,694 |
About this award
The National Heart Lung and Blood Institute awarded a delivery order valued at $761,385.23 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. on June 3, 2019, with completion targeted for March 31, 2022. This contract falls under the Production Assistance for Cellular Therapies–Cell Processing Facilities (PACT-CPF) master IDIQ vehicle and supports cell manufacturing and process development services for a Factor VIII TCR-engineered Treg cell product (PCT0025-01). The award was structured as a cost, no-fee delivery order with no small business set-aside and is being performed at Moffitt's Tampa, Florida facility.
As a National Cancer Institute-designated comprehensive cancer center, H. Lee Moffitt Cancer Center brings substantial expertise in advanced cellular therapies and immunotherapy development to this engagement. The contract represents the federal government's investment in specialized cell processing capabilities and manufacturing infrastructure necessary to advance regenerative and cellular medicine initiatives. Moffitt's established track record in cancer research, clinical trial execution, and translational medicine positions the organization to deliver the technical expertise required for engineering and manufacturing this specialized Treg cell therapeutic product.
Quick answers
Who was awarded contract 75N92019F00074?
75N92019F00074 was awarded to H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on June 3, 2019.
How much is contract 75N92019F00074 worth?
The government has obligated $761,385 on 75N92019F00074.
Is contract 75N92019F00074 an order under another contract?
Yes. 75N92019F00074 is a delivery order under HHSN268201600013I, an indefinite delivery contract, on Production Assistance for Cellular Therapies - Cell Processing Facilities (PACT-CPF).
Was contract 75N92019F00074 competed?
The extent of competition for 75N92019F00074 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award